In the past year some publicity has been spread with the obvious purpose to create doubts about the accuracy of our COVID-19 IgG/IgM rapid test cassette (BNCP-402). You probably noticed… You might also have noticed that Biozek, as a professional manufacturer of top-quality products, has not really taken any substantial effort to counter these false accusations by using the same public channels that were used to damage the image of our company and products.
Instead we chose to continue to focus on the quality of our products and the development of our new products such as the Covid-19 Rapid Antigen. I the mean time we continued to receive the support from our global steady clients (governmental and corporate) who prefer to believe the results of clinical studies instead of the suggestive articles that were written by non-specialists.
We were able to maintain our motivation thanks to these governments and companies to whom we are highly grateful. We also thank the independent laboratories who approved our product through clinical trials and validation studies of which you will find some examples below (links)
In France there is an article about the approved tests and the government website which confirms that the tests met the requirements.
In The Netherlands the following reports have been published about the Biozek COVID-19 IgG/IgM rapid test cassette:
In Norway the NOKLUS (Norwegian Organization for Quality improvement of Laboratory examination) has recently tested several rapid test for the detection of antibody for COVID-19. Biozek has scored good and acceptable scores.
We thank you for your trust in our product and if there are any questions or remarks, please do not hesitate to contact us.